Skip to main content

Table 4 Changes in baseline to endpoint measures for lipid profile in two groups

From: Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Variables

Mean ± SD

Placebo(n = 28)

Mean ± SD

Ellagic acid (n = 29)

P1

Chol(mg/dL)

Baseline

192 ± 51.03

197.13 ± 48.71

0.801

End

190.28 ± 58.51

178.09 ± 45.46

0.024

P2

0.754

0.0349

 

Mean Changes

-1.72 ± 7.48

-19.04 ± 3.25

0.031

TG (mg/dL)

Baseline

159.19 ± 19.61

163.28 ± 20.55

0.586

End

157.2 ± 19.29

145.33 ± 16.04

0.042

P2

0.59

0.04

 

Mean Changes

-1.99 ± 0.32

-17.95 ± 4.51

0.043

HDL (mg/dL)

Baseline

37.08 ± 6.27

36.13 ± 7.7

0.55

End

37 ± 6.25

39.2 ± 8.02

0.124

P2

0.61

0.082

 

Mean Changes

-0.08 ± 0.02

3.07 ± 0.32

0.23

LDL (mg/dL)

Baseline

123.08 ± 40.05

128.34 ± 36.89

0.714

End

122.28 ± 44.11

108.7 ± 35.19

0.04

P2

0.8

0.031

 

Mean Changes

-0.8 ± 4.06

-19.64 ± 1.7

0.044

  1. Data are expressed as means ± SD. Chol Cholesterol, TG Triglyceride, HDL High-Density lipoprotein, LDL Low-density lipoprotein
  2. P1: Comparison of the mean of lipid profile between the two groups of Ellagic acid and placebo (Independent samples t-test)
  3. P2: Comparison of mean of lipid profile in each group at baseline and end of study (Paired samples t-test)